Blue Trust’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$651 Sell
32
-8
-20% -$187 ﹤0.01% 2251
2026
Q2
$1.03K Hold
40
– – ﹤0.01% 2293
2026
Q1
$768 Hold
40
– – ﹤0.01% 2293
2025
Q4
$660 Hold
40
– – ﹤0.01% 2352
2025
Q3
$581 Hold
40
– – ﹤0.01% 2402
2025
Q2
$560 Buy
+40
New +$563 ﹤0.01% 2306
2024
Q4
– Sell
-72
Closed -$1.67K – 2579
2024
Q3
$1.67K Sell
72
-10
-12% -$248 ﹤0.01% 2613
2024
Q2
$1.68K Buy
+82
New +$1.57K ﹤0.01% 2465
2023
Q3
– Sell
-15
Closed – – 2094
2023
Q2
$0 Buy
15
+8
+114% +$225 ﹤0.01% 2130
2023
Q1
$0 Sell
7
-1
-13% -$28 ﹤0.01% 2382
2022
Q4
$0 Buy
8
+2
+33% +$60 ﹤0.01% 2289
2022
Q3
$0 Buy
+6
New +$195 ﹤0.01% 2145

Other funds holding DNLI

Blue Trust's DNLI Position: Q3 2026 in Review

Blue Trust reduced its Denali Therapeutics (DNLI) stake by 20% in Q3 2026, selling an estimated $187 and leaving 32 shares worth $651. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Blue Trust first reported a position in DNLI in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.68K in Q2 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Blue Trust held 32 shares of Denali Therapeutics worth $651 as of Q3 2026.
  • Blue Trust sold 8 Denali Therapeutics shares in Q3 2026, an estimated $187.
  • Denali Therapeutics made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2251 holding.
  • Blue Trust first reported a position in Denali Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Blue Trust's Denali Therapeutics position peaked at $1.68K in Q2 2024.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.